Accelerating clinical trials with precision logistics (Sponsored)
The Top Line27 Huhti

Accelerating clinical trials with precision logistics (Sponsored)

Speed, precision, and visibility are critical to clinical trial success, and logistics plays a central role in delivering all three. In this interview, Manishaa O’Brien, director of commercial operations at Marken UPS Healthcare Precision Logistics, shares how the Laboratory Advantage service line is helping central labs and sponsors accelerate timelines while maintaining sample integrity and compliance.

O’Brien discusses how Marken’s global network, combined with its air and ground fleet, connects clinical sites worldwide and expands access to diverse patient populations. She explains how enhanced tracking, integrated data systems and a 99.5% on-time performance rate support reliable, end-to-end visibility for lab partners. Dedicated account management and tailored logistics solutions further strengthen collaboration and help ensure regulatory requirements are met.

The conversation also explores key trends shaping the future of clinical trial logistics, including increasing complexity, the rise of AI-driven routing and the growing importance of sustainability. From automation to eco-friendly packaging innovations, Marken is building a more efficient and resilient supply chain. Watch the full interview to learn how these advancements are helping clinical trials move faster and smarter.

See omnystudio.com/listener for privacy information.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(100)

How we picked the Fierce 15

How we picked the Fierce 15

What does it mean to be a Fierce 15 biotech in 2026? With this year’s list unveiled, the Fierce Biotech team gets together to discuss what the winners tell us about the state of the sector.In this wee...

9 Loka 23min

Locking in on pharma’s consumerization trend

Locking in on pharma’s consumerization trend

With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. Now, the CEO of a buzzy pattern-hair-loss biotech is eyeing opportunities in an evolving m...

2 Loka 18min

Fierce Pharma Week: A look at the biggest trends, campaigns and conversations

Fierce Pharma Week: A look at the biggest trends, campaigns and conversations

Fierce Pharma Week brought thousands of people to Philadelphia for four days of conversations about pharma marketing, commercialization, medical affairs and communications. In this episode of "The Top...

25 Syys 24min

Inside the growing world of biopharma prediction markets

Inside the growing world of biopharma prediction markets

Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. But they also create a new set of risks for an industry where employees, researche...

18 Syys 23min

Clinical trials reach a new automation inflection point (Sponsored)

Clinical trials reach a new automation inflection point (Sponsored)

Clinical development organizations are facing mounting pressure to do more with increasingly complex protocols, larger data sets and tighter timelines. While automation has improved individual process...

14 Syys 17min

The future of RAS inhibitors

The future of RAS inhibitors

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach...

11 Syys 29min

The people who stayed with the problem

The people who stayed with the problem

The 2026 Fierce 50 includes people and organizations working on very different problems across biopharma and healthcare, from designing new proteins and developing cancer medicines to protecting vacci...

4 Syys 25min

Why Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored)

Why Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored)

The promise of precision medicine depends on more than scientific innovation. It also depends on whether eligible patients can be identified, tested and connected to the most appropriate treatment. In...

2 Syys 13min

Suosittua kategoriassa Politiikka ja uutiset

uutiscast
vallattomat
aikalisa
politiikan-puskaradio
rss-viihde-media
rss-ootsa-kuullut-tasta
ootsa-kuullut-tasta-2
rss-vaalirankkurit-podcast
rss-voi-venaja
the-ulkopolitist
tervo-halme
otetaan-yhdet
rss-asiastudio
rss-kaikki-uusiksi
rss-ulkopoditiikkaa
rss-toisten-taskuilla
rss-vihrea-tuuma
rss-raha-talous-ja-politiikka
rss-girls-finish-f1rst
rss-podme-livebox